Tau Thr181 phosphorylation

Tau Thr181 phosphorylation

Phosphorylation of tau protein at threonine 181 (Tau Thr181 phosphorylation) is a hallmark of Alzheimer’s disease (AD) pathology. Elevated levels of Tau Thr181 phosphorylation have been detected in both cerebrospinal fluid (CSF) and plasma of individuals with AD, correlating with amyloid-β deposition and tau pathology. Notably, plasma Tau Thr181 phosphorylation levels begin to rise during the preclinical stages of AD, even when only subtle changes in amyloid-β pathology are present, and continue to increase through mild cognitive impairment (MCI) and into the dementia stages. This makes Tau Thr181 phosphorylation a valuable biomarker for early detection and monitoring of disease progression.

Studies have demonstrated that novel p-tau biomarkers, including Tau Thr181 phosphorylation, increase prominently in the preclinical stages of Alzheimer’s continuum, accurately differentiating amyloid-β-positive from amyloid-β-negative cognitively unimpaired individuals. For instance, plasma Tau Thr181 phosphorylation levels are mildly but significantly elevated in the preclinical stage, supporting the idea that early changes in neuronal tau metabolism occur in response to amyloid-β exposure. These findings suggest that Tau Thr181 phosphorylation can serve as a predictive biomarker for Alzheimer’s pathophysiology, aiding in the identification of individuals at risk before clinical symptoms emerge.

The utility of Tau Thr181 phosphorylation as a biomarker extends beyond early detection. Elevated serum levels of Tau Thr181 phosphorylation have been associated with the progression from pre-MCI to MCI and AD, reflecting the severity of the disease. This correlation underscores the potential of Tau Thr181 phosphorylation not only in diagnosing AD but also in monitoring disease progression and evaluating therapeutic efficacy. As a minimally invasive and cost-effective biomarker, Tau Thr181 phosphorylation offers significant advantages for widespread clinical application, facilitating timely intervention and improved patient outcomes.